Mortality is persistently increased in Hodgkin's lymphoma survivors

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1632-1639

  Kiserud, Cecilie E ^a   Loge, Jon Håvard ^a   Fosså, Alexander ^a   Holte, Harald ^a   Cvancarova, Milada ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Causes of death; Fatigue; Hodgkin's lymphoma; Matched controls; Mortality

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; FATIGUE; FEMALE; HEALTH SURVEY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; AGED; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; NORWAY; STATISTICS AND NUMERICAL DATA; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CAUSE OF DEATH; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NORWAY; SURVIVORS; YOUNG ADULT;

EID: 77952673858     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.010     Document Type: Article

References (26)

1. Abrahamsen A.F., Loge J.H., Hannisdal E., et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol 38 4 (1999) 511-515
2. Aleman B.M., van den Belt-Dusebout A.W., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 18 (2003) 3431-3439
3. Aleman B.M.P., van den Belt-Dusebout A., De Bruin M.L., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 5 (2007) 1878-1886
4. Behringer K., Breuer K., Reineke T., et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23 30 (2005) 7555-7564
5. Hodgson D.C., Gilbert E.S., Dores G.M., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25 12 (2007) 1489-1497
6. Howell S.J., Radford J.A., Ryder W.D., and Shalet S.M. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 17 5 (1999) 1493-1498
7. Howell S.J., Radford J.A., Adams J.E., and Shalet S.M. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol 52 (2000) 609-616
8. Hull M.C., Morris C.G., Pepine C.J., and Mendenhall N.P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290 21 (2003) 2831-2837
9. Viviani S., Santoro A., Ragni G., et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21 5 (1985) 601-605
10. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 8 (2002) 2101-2108
11. Provencio M., Millan I., Espana P., et al. Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin's disease. Clin Cancer Res 14 16 (2008) 5300-5305
12. Favier O., Heutte N., Stamatoullas-Bastard A., et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer (2009)
13. Mols F., Vingerhoets A.J., Coebergh J.W., et al. Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: a population-based study. Eur J Cancer 42 16 (2006) 2794-2801
14. Wettergren L., Bjorkholm M., Axdorph U., and Langius-Eklof A. Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Qual Life Res 13 8 (2004) 1369-1379
15. Kornblith A.B., Herndon J.E., Zuckerman E., et al. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol 9 3 (1998) 297-306
16. Ruffer J.U., Flechtner H., Tralls P., et al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39 15 (2003) 2179-2186
17. Abrahamsen A.F., Loge J.H., Hannisdal E., Holte H., and Kvaloy S. Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer 34 12 (1998) 1865-1870
18. Loge J.H., Abrahamsen A.F., Ekeberg O., and Kaasa S. Hodgkin's disease survivors more fatigued than the general population. J Clin Oncol 17 1 (1999) 253-261
19. Abrahamsen A.F., Egeland T., Hansen S., et al. Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer 33 14 (1997) 2380-2383
20. Holte H., Mella O., Wist E., et al. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Acta Oncol 35 Suppl. 80 (1996)
21. Chalder T., Berelowitz G., Pawlikowska T., et al. Development of a fatigue scale. J Psychosom Res 37 (1993) 147-153
22. Pintilie M. Competing risks: a practical perspective (2006), Wiley
23. Raboud J., and Breslow N.E. Efficiency gains from the addition of controls to matched sets in cohort studies. Stat Med 8 8 (1989) 977-985
24. Barchielli A., and Balzi D. Nine-year follow-up of a survey on smoking habits in Florence (Italy): higher mortality among non-responders. Int J Epidemiol 31 5 (2002) 1038-1042
25. Heilbrun L.K., Nomura A., and Stemmermann G.N. The effects of non-response in a prospective study of cancer: 15-year follow-up. Int J Epidemiol 20 2 (1991) 328-338
26. Engert A., Diehl V., Franklin J., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009)